Table 1 Data sources for the Mendelian Randomisation analysis in the current study
Phenotype | Sample size # | Imputation reference panel | Ancestry | Source |
|---|---|---|---|---|
Olink protein levels | ||||
Inflammation panel (INF1) | 4994 | 1000 Genomes Phase 3 + UK10K | European | INTERVAL study (unpublished data) |
Cardiovascular panels (CVD2 & 3) | ||||
Neurology panel (NEURO) | ||||
Primary outcomes | ||||
Any stroke | 40,585/406,111 | 1000 Genomes phase 1 | European | 17 studies (Malik et al.)22 |
Ischaemic stroke | 34,217/406,111 | |||
Large artery stroke | 4373/406,111 | |||
Cardioembolic stroke | 7193/406,111 | |||
Small vessel stroke | 5386/406,111 | |||
Secondary outcomes | ||||
Atrial fibrillation | 60,620/970,216 | HRC | European | 6 Studies (Nielsen, et al.)76 |
Type 2 diabetes | 74,124/824,006 | HRC | European | 32 Studies (Mahajan, et al.)77 |
Body mass index | 694,649 | HRC | European | GIANT + UK Biobank (Pulit, et al.)79 |
Tobacco and alcohol use | HRC | European | 29 Studies (Liu, et al.)80 | |
AgeSmk | 341,427 | |||
CigDay | 337,334 | |||
SmkCes | 547,219 | |||
SmkInit | 1,232,091 | |||
DrnkWk | 941,280 | |||
Blood pressure (BP) | 445,415 | HRC | European | UK Biobank (Surendran, et al.)75 |
Systolic BP | ||||
Diastolic BP | ||||
Pulse pressure | ||||
White Matter Hyperintensity | 42,310 | HRC | Trans-ethnic, mainly European | UK Biobank + CHARGE + stroke patients (Persyn et al., 2020) 78 |
On-target side-effects evaluation | ||||
784 Phenotypes | 408,961 | HRC | European | UK Biobank (Zhou, et al.)91 |
